Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03397264 · ClinicalTrials.gov registry record · Phase 1
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
A Phase 1 study of Diabetic Macular Edema, sponsored by Opthea Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT03397264 is a Phase 1 study of Diabetic Macular Edema that has completed, run by Opthea Limited. The registered enrollment target is 153 participants, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT03397264, a Phase 1 study of Diabetic Macular Edema, has completed, sponsored by Opthea Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
A two part, multi-center study consisting of a Phase 1b open label, sequential dose escalation followed by a Phase 2a randomized, double-masked, dose expansion evaluating OPT-302 in combination with aflibercept in participants with persistent central-involved Diabetic Macular Edema.
Conditions Studied
Interventions
- BIOLOGICAL Aflibercept
- BIOLOGICAL OPT-302
- OTHER Sham intravitreal injection
Study Locations (20)
California
- Opthea Investigational Site - Bakersfield
- Opthea Investigational Site - Beverly Hills
- Opthea Investigational Site - Redlands
- Opthea Investigational Site - Sacramento
- Opthea Investigational Site - Santa Ana
Florida
- Opthea Investigational Site - Boynton Beach
- Opthea Investigational Site - Fort Myers
- Opthea Investigational Site - Melbourne
- Opthea Investigational Site - Pensacola
- Opthea Investigational Site - St. Petersburg
Nevada
- Opthea Investigational Site - Las Vegas
- Opthea Investigational Site - Reno
Arizona
- Opthea Investigational Site - Phoenix
Colorado
- Opthea Investigational Site - Colorado Springs
Georgia
- Opthea Investigational Site - Augusta
Indiana
- Opthea Investigational Site - Indianapolis
Iowa
- Opthea Investigational Site - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2020-06-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03397264
The ClinicalTrials.gov registry entry for NCT03397264 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,792-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (96% lower). The listed sponsor is Opthea Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 3 interventions - of which Aflibercept is the first listed.
NCT03397264 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Nevada.
Frequently Asked Questions
What is clinical trial NCT03397264 about?
NCT03397264 is a clinical study titled "A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema". A two part, multi-center study consisting of a Phase 1b open label, sequential dose escalation followed by a Phase 2a randomized, double-masked, dose expansion evaluating OPT-302 in combination with aflibercept in participants with persistent central-involved Diabetic Macular Edema.
What is the current status of trial NCT03397264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2018-01-16. Estimated completion is 2020-06-11.
What conditions does trial NCT03397264 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT03397264?
The interventions under investigation include: Aflibercept (BIOLOGICAL), OPT-302 (BIOLOGICAL), Sham intravitreal injection (OTHER).
Who is sponsoring clinical trial NCT03397264?
This trial is sponsored by Opthea Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03397264 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.